Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17364149 | 0.99 | DRD2 (0.46) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL29848871 | 0.99 | DRD2 (0.46) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18394841 | 0.95 | DRD2 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18395601 | 0.82 | DRD3 (0.47) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL17364174 | 0.82 | OPRM1 (0.49) | DRD2DRD4DRD3DRD1OPRL1 | |
| Hydrochloric Acid SCHEMBL28638282 | 0.81 | OPRL1 (0.54) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18408637 | 0.81 | DRD3 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL31280938 | 0.81 | KMT2A (0.47) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL24489451 | 0.79 | OPRL1 (0.65) | DRD2OPRL1SIGMAR1OPRM1OPRD1 | |
| SCHEMBL17411365 | 0.79 | OPRM1 (0.45) | OPRL1SIGMAR1OPRM1OPRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | disclosed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2017015609-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | WO | disclosed |
| US-7923459-B2 | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-04-12 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2007-10-11 | — | — | US | disclosed |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2007-10-11 | — | — | US | disclosed |
| WO-2006040155-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | DRD2 66/4885DRD4 13/4885DRD3 37/4885 |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | DRD2 7/4885DRD4 14/4885DRD3 21/4885 |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | DRD2 15/4885DRD4 17/4885DRD3 55/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885DRD4 29/4885DRD3 30/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | GPX4, SQOR, SRM | DRD2 1056/4885DRD4 447/4885DRD3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.